top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

David Smith Biography and Net Worth

CFO of Charles River Laboratories International

David R. Smith joined Charles River with the acquisition of Argenta and BioFocus in April 2014. Mr. Smith assumed the role of Corporate Vice President, Charles River Early Discovery Services, following the completion of the acquisition, and in October 2014, was promoted to Corporate Senior Vice President, Global Discovery Services. In August 2015, Mr. Smith was promoted to Corporate Executive Vice President and Chief Financial Officer. In this role, Mr. Smith leads the Company’s global finance organization and is responsible for overseeing Accounting, Tax, Treasury, Investor Relations, and Internal Audit. He is a member of the company’s Executive Committee.

Prior to joining Charles River, Mr. Smith had been Chief Executive Officer of Galapagos Services, the contract research services division of Belgian biotech Galapagos NV, which included Argenta and BioFocus. He had held this position since August 2013. Previously, he was Chief Financial Officer of Cambridge University Hospitals from 2007 to 2013, and of Galapagos NV between 2006 and 2007, during which time he played a key role in several merger and acquisition projects to build the services division. Mr. Smith held Marketing Company Chief Financial Officer and R&D Finance roles within AstraZeneca in the United Kingdom, Sweden, Hungary, and the Netherlands from 1997 to 2005, and worked as a Chartered Accountant with PricewaterhouseCoopers in the United Kingdom and Dubai between 1989 and 1997.

Mr. Smith received a B.Sc. Honours degree in Molecular Biophysics from the University of Leeds.

What is David Ross Smith's net worth?: The estimated net worth of David Ross Smith is at least $4.39 million as of May 4th, 2021. Mr. Smith owns 18,167 shares of Charles River Laboratories International stock worth more than $4,393,689 as of April 23rd. This net worth estimate does not reflect any other investments that Mr. Smith may own. Learn More about David Ross Smith's net worth.
How do I contact David Ross Smith?: The corporate mailing address for Mr. Smith and other Charles River Laboratories International executives is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. Charles River Laboratories International can also be reached via phone at (781) 222-6000 and via email at [email protected]. Learn More on David Ross Smith's contact information.
Has David Ross Smith been buying or selling shares of Charles River Laboratories International?: David Ross Smith has not been actively trading shares of Charles River Laboratories International in the last ninety days. Most recently, David Ross Smith sold 1,750 shares of the business's stock in a transaction on Monday, August 9th. The shares were sold at an average price of $407.40, for a transaction totalling $712,950.00. Learn More on David Ross Smith's trading history.
Who are Charles River Laboratories International's active insiders?: Charles River Laboratories International's insider roster includes William Barbo (VP), Robert Bertolini (Director), Stephen Chubb (Director), Victoria Creamer (EVP), James Foster (CEO), Birgit Girshick (VP), Michael Knell (CAO), Deborah Kochevar (Director), Joseph LaPlume (EVP), George Massaro (Director), Shannon Parisotto (EVP), David Smith (CFO), and Richard Wallman (Director). Learn More on Charles River Laboratories International's active insiders.
Are insiders buying or selling shares of Charles River Laboratories International?: During the last year, Charles River Laboratories International insiders bought shares 3 times. They purchased a total of 7,942 shares worth more than $1,447,729.04. During the last year, insiders at the medical research company sold shares 7 times. They sold a total of 23,211 shares worth more than $5,481,396.41. The most recent insider tranaction occured on February, 29th when EVP Victoria L Creamer sold 5,000 shares worth more than $1,268,500.00. Insiders at Charles River Laboratories International own 1.3% of the company. Learn More about insider trades at Charles River Laboratories International.
Information on this page was last updated on 2/29/2024.

David Ross Smith Insider Trading History at Charles River Laboratories International

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/9/2021	Sell	1,750	$407.40	$712,950.00
5/4/2021	Sell	3,305	$340.01	$1,123,733.05	18,167
4/22/2021	Sell	3,845	$330.00	$1,268,850.00	18,707
4/15/2021	Sell	2,000	$320.00	$640,000.00	14,862
2/19/2021	Sell	8,656	$290.63	$2,515,693.28	17,303
2/24/2020	Sell	8,211	$166.72	$1,368,937.92	25,219
2/13/2020	Sell	4,500	$170.29	$766,305.00	21,978
8/12/2019	Sell	1,249	$130.36	$162,819.64	19,327
2/27/2019	Sell	2,158	$141.07	$304,429.06	20,573
2/25/2019	Sell	4,000	$145.43	$581,720.00	24,262
11/12/2018	Sell	1,866	$134.49	$250,958.34	12,341
8/13/2018	Sell	1,249	$120.05	$149,942.45	13,690
5/1/2018	Sell	945	$104.23	$98,497.35	13,723
2/28/2018	Sell	100	$108.43	$10,843.00	13,103
2/26/2018	Sell	3,868	$107.35	$415,229.80	18,483
2/16/2018	Sell	3,639	$109.07	$396,905.73	15,110
1/2/2018	Sell	5,486	$109.53	$600,881.58
8/14/2017	Sell	2,552	$67.10	$171,239.20	11,671
6/8/2017	Sell	945	$95.00	$89,775.00	14,203
3/3/2017	Sell	3,890	$88.12	$342,786.80	17,085

David Ross Smith Buying and Selling Activity at Charles River Laboratories International

Charles River Laboratories International Company Overview

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Today's Range

Now: $239.98

$236.22

$242.86

50 Day Range

MA: $254.27

$226.78

$273.43

2 Week Range

Now: $239.98

$161.65

$275.00

Volume

611,881 shs

Average Volume

549,469 shs

Market Capitalization

$12.36 billion

P/E Ratio

26.06

Dividend Yield

N/A

Beta

1.4